Pharma and biotech market intelligence, pipeline analysis, deal flow, forecasting and decision systems for strategy, BD and investor teams.
A CMO reviews a Phase 2 protocol. The team has designed a traditional randomized, double-blind, placebo-controlled trial with a fixed sample size of 300 patients. Enrollment is projected to take…
In 2023, Chinese biotechs signed over $50 billion in total deal value with Western pharma companies. By mid-2024, that pace…
Hamza
During the pandemic, a Phase 3 trial for a cardiovascular drug shifted from 100% site-based visits to a hybrid model…
Hamza
After three years of pandemic recovery, the senior living market in 2025 has reached an inflection point. National occupancy rates…
Hamza
A market access team prepares an HTA submission for a new oncology drug. They build a dossier with strong clinical…
Hamza
Drug patents are among the most misunderstood aspects of pharmaceutical business development. A compound may be described as “protected until…
Hamza
Clinical trial failure rates remain one of the most important metrics in pharmaceutical R&D. Understanding clinical trial failure rates helps…
Hamza
You join a pharma company’s strategy team. In your first week, a colleague says: “The target has a Phase 2b…
Hamza
By 2030, every Baby Boomer in the United States will be over 65. Globally, the 65+ population will exceed 1…
Hamza
A drug receives regulatory approval. Clinical trial results are strong. Physicians are interested. Investors are optimistic. Yet one year after…
Hamza
Join 200+ marketers getting actionable strategies every Tuesday.
No spam. Unsubscribe anytime.
